Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 37Sarcoma 3Thoracic 2Dermatologic 2CNS 2Other solid neoplasm 1Other 1Endocrine 1Breast 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 299Solid Tumors 184Advanced Solid Tumors 168Solid Tumor 152Mesothelioma, Malignant 152Mesothelioma 121Advanced Solid Tumor 97Carcinoma, Non-Small-Cell Lung 50Retinoblastoma 48Lung Neoplasms 37Solid Tumor, Adult 36Sarcoma 31Ovarian Neoplasms 29Neoplasms 27Stomach Neoplasms 26Carcinoma, Renal Cell 26Small Cell Lung Carcinoma 25Melanoma 25Pancreatic Neoplasms 24Breast Neoplasms 24Unspecified Childhood Solid Tumor, Protocol Specific 23Esophageal Neoplasms 21Uterine Cervical Neoplasms 20Solid Tumours 20Solitary Fibrous Tumor, Pleural 19Osteosarcoma 19Colorectal Neoplasms 17Neuroblastoma 16Head and Neck Neoplasms 16Carcinoma, Hepatocellular 16

Interventions

LY2940680 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Laryngeal Diseases × Other solid neoplasm × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡